Dr. Carpenter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-228-1000
Education & Training
University of Sydney Faculty of MedicineClass of 1988
Certifications & Licensure
WA State Medical License 2001 - 2025
AK State Medical License 2022 - 2024
Publications & Presentations
PubMed
- Vaccine hesitancy and routine revaccination among adult HCT survivors in the United States: A convergent mixed methods analysis.Mihkai M Wickline, Paul A Carpenter, Jeffrey R Harris, Sarah J Iribarren, Kerryn W Reding
Vaccine. 2024-12-02 - ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies.Piyanuch Kongtim, Pongthep Vittayawacharin, Jun Zou, Samer Srour, Brian Shaffer
Transplantation and Cellular Therapy. 2024-12-01 - Correction: Novel factors to predict respiratory viral disease progression in allogeneic hematopoietic cell transplant recipients.Chikara Ogimi, Hu Xie, Alpana Waghmare, Keith R Jerome, Wendy M Leisenring
Bone Marrow Transplantation. 2024-12-01
Press Mentions
- FDA Approves Ibrutinib (Imbruvica) for Graft-Versus-Host Disease in Children, Young AdultsAugust 25th, 2022
- (Ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host DiseaseAugust 24th, 2022
- The U.S. Food and Drug Administration Approved the Use of IMBRUVICA for the Treatment of Pediatric Patients One Year and Older with cGVHD After Failure of One or More Lines of Systemic TherapyAugust 24th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
